1
|
Abreu de Oliveira WA, Moens S, El Laithy Y, van der Veer BK, Athanasouli P, Cortesi EE, Baietti MF, Koh KP, Ventura JJ, Amant F, Annibali D, Lluis F. Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. Front Oncol 2021; 11:705384. [PMID: 34367990 PMCID: PMC8340846 DOI: 10.3389/fonc.2021.705384] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2021] [Accepted: 06/28/2021] [Indexed: 12/11/2022] Open
Abstract
Triple-Negative Breast Cancer (TNBC) is the most aggressive breast cancer subtype, characterized by limited treatment options and higher relapse rates than hormone-receptor-positive breast cancers. Chemotherapy remains the mainstay treatment for TNBC, and platinum salts have been explored as a therapeutic alternative in neo-adjuvant and metastatic settings. However, primary and acquired resistance to chemotherapy in general and platinum-based regimens specifically strongly hampers TNBC management. In this study, we used carboplatin-resistant in vivo patient-derived xenograft and isogenic TNBC cell-line models and detected enhanced Wnt/β-catenin activity correlating with an induced expression of stem cell markers in both resistant models. In accordance, the activation of canonical Wnt signaling in parental TNBC cell lines increases stem cell markers' expression, formation of tumorspheres and promotes carboplatin resistance. Finally, we prove that Wnt signaling inhibition resensitizes resistant models to carboplatin both in vitro and in vivo, suggesting the synergistic use of Wnt inhibitors and carboplatin as a therapeutic option in TNBC. Here we provide evidence for a prominent role of Wnt signaling in mediating resistance to carboplatin, and we establish that combinatorial targeting of Wnt signaling overcomes carboplatin resistance enhancing chemotherapeutic drug efficacy.
Collapse
Affiliation(s)
| | - Stijn Moens
- Leuven Cancer Institute (LKI), Department of Oncology, Gynecological Oncology Lab 3000, KU Leuven, Leuven, Belgium
| | - Youssef El Laithy
- Stem Cell Institute, Department of Development and Regeneration, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Bernard K van der Veer
- Stem Cell Institute, Department of Development and Regeneration, Laboratory for Stem Cell and Developmental Epigenetics, KU Leuven, Leuven, Belgium
| | - Paraskevi Athanasouli
- Stem Cell Institute, Department of Development and Regeneration, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Emanuela Elsa Cortesi
- Translational Cell and Tissue Research - Department of Imaging & Pathology, KU Leuven, Leuven, Belgium
| | | | - Kian Peng Koh
- Stem Cell Institute, Department of Development and Regeneration, Laboratory for Stem Cell and Developmental Epigenetics, KU Leuven, Leuven, Belgium
| | - Juan-Jose Ventura
- Translational Cell and Tissue Research - Department of Imaging & Pathology, KU Leuven, Leuven, Belgium
| | - Frédéric Amant
- Leuven Cancer Institute (LKI), Department of Oncology, Gynecological Oncology Lab 3000, KU Leuven, Leuven, Belgium.,Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (AvL-NKI), University Medical Center (UMC), Amsterdam, Netherlands
| | - Daniela Annibali
- Leuven Cancer Institute (LKI), Department of Oncology, Gynecological Oncology Lab 3000, KU Leuven, Leuven, Belgium.,Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | - Frederic Lluis
- Stem Cell Institute, Department of Development and Regeneration, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| |
Collapse
|
2
|
Moens S, Zhao P, Baietti MF, Marinelli O, Van Haver D, Impens F, Floris G, Marangoni E, Neven P, Annibali D, Sablina AA, Amant F. The mitotic checkpoint is a targetable vulnerability of carboplatin-resistant triple negative breast cancers. Sci Rep 2021; 11:3176. [PMID: 33542435 PMCID: PMC7862668 DOI: 10.1038/s41598-021-82780-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 01/21/2021] [Indexed: 01/24/2023] Open
Abstract
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, lacking effective therapy. Many TNBCs show remarkable response to carboplatin-based chemotherapy, but often develop resistance over time. With increasing use of carboplatin in the clinic, there is a pressing need to identify vulnerabilities of carboplatin-resistant tumors. In this study, we generated carboplatin-resistant TNBC MDA-MB-468 cell line and patient derived TNBC xenograft models. Mass spectrometry-based proteome profiling demonstrated that carboplatin resistance in TNBC is linked to drastic metabolism rewiring and upregulation of anti-oxidative response that supports cell replication by maintaining low levels of DNA damage in the presence of carboplatin. Carboplatin-resistant cells also exhibited dysregulation of the mitotic checkpoint. A kinome shRNA screen revealed that carboplatin-resistant cells are vulnerable to the depletion of the mitotic checkpoint regulators, whereas the checkpoint kinases CHEK1 and WEE1 are indispensable for the survival of carboplatin-resistant cells in the presence of carboplatin. We confirmed that pharmacological inhibition of CHEK1 by prexasertib in the presence of carboplatin is well tolerated by mice and suppresses the growth of carboplatin-resistant TNBC xenografts. Thus, abrogation of the mitotic checkpoint by CHEK1 inhibition re-sensitizes carboplatin-resistant TNBCs to carboplatin and represents a potential strategy for the treatment of carboplatin-resistant TNBCs.
Collapse
Affiliation(s)
- Stijn Moens
- VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.,Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium
| | - Peihua Zhao
- VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.,Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium
| | - Maria Francesca Baietti
- VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.,Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium
| | - Oliviero Marinelli
- Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium.,School of Pharmacy, University of Camerino, Camerino, Italy
| | - Delphi Van Haver
- VIB Center for Medical Biotechnology, Ghent, Belgium.,Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.,VIB Proteomics Core, Ghent, Belgium
| | - Francis Impens
- VIB Center for Medical Biotechnology, Ghent, Belgium.,Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.,VIB Proteomics Core, Ghent, Belgium
| | - Giuseppe Floris
- Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.,Department of Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Elisabetta Marangoni
- Translational Research Department, Institut Curie, PSL Research University, Paris, France
| | - Patrick Neven
- Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium.,Department of Obstetrics and Gynecology, University Hospitals Leuven, 3000, Leuven, Belgium
| | - Daniela Annibali
- Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium.,Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Anna A Sablina
- VIB-KU Leuven Center for Cancer Biology, VIB, Leuven, Belgium.,Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium
| | - Frédéric Amant
- Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), 3000, Leuven, Belgium. .,Department of Obstetrics and Gynecology, University Hospitals Leuven, 3000, Leuven, Belgium. .,Centre for Gynecologic Oncology Amsterdam (CGOA), Antoni Van Leeuwenhoek-Netherlands Cancer Institute (AvL-NKI), University Medical Center (UMC), Amsterdam, The Netherlands.
| |
Collapse
|
3
|
Van Nyen T, Duarte JA, Rossi M, Planque M, Zaal E, Talebi A, Moens S, Eelen G, Horlings H, Swinnen J, Berkers C, Carmeliet P, Agami R, Fendt SM, Lambrechts D, Annibali D, Amant F. Abstract A75: Serine auxotrophy: A novel metabolic vulnerability of platinum-resistant ovarian cancer? Clin Cancer Res 2020. [DOI: 10.1158/1557-3265.ovca19-a75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Ovarian cancer accounts for the highest number of gynecologic-associated deaths in the developed world, and resistance to platinum-based therapy represents a major clinical and societal challenge in patients’ management. Since metabolism is intertwined with signaling pathways controlling cell death, we aimed to investigate to what extent metabolic adaptations could contribute to the development of the resistant phenotype. By performing isotope-labeled 13C-glucose tracer analysis in vitro, we found that, when they become resistant to platinum, ovarian cancer cells stop to synthetize serine and are characterized by significantly lower intracellular levels of this amino acid compared to sensitive cells. However, serine is required for cellular growth and survival, and resistant cells increase its uptake from the medium, becoming exquisitely vulnerable to serine starvation. We showed that, although resistant cells accumulate DNA damage upon platinum treatment, they have a higher capacity of repairing it because of increased poly(ADP)-ribose polymerase (PARP) activity, compared to the sensitive ones. Since PARP enzymes are major oxidized nicotinamide adenine dinucleotide (NAD+)-consuming enzymes, we collected evidence that serine synthesis downregulation, as a consequence of central carbon metabolic reshuffling, provides resistant cells with the advantage of sparing NAD+, thus sustaining PARP activation and allowing a more efficient DNA repair. We confirmed that downregulation of serine synthesis is a peculiar trait of resistant tumors also in vivo, using patient-derived xenografts (PDX) ovarian cancer models subjected to serine/glycine free diet. Moreover, analysis of The Cancer Genome Atlas Consortium (TCGA) ovarian cancer dataset revealed that tumors from platinum-resistant patients are characterized by a downregulation of serine biosynthetic enzymes, suggesting that serine auxotrophy could represent a novel and exploitable vulnerability of platinum-resistant ovarian cancers.
Citation Format: Tom Van Nyen, Joao A.G. Duarte, Matteo Rossi, Mélanie Planque, Esther Zaal, Ali Talebi, Stijn Moens, Guy Eelen, Hugo Horlings, Johan Swinnen, Celia Berkers, Peter Carmeliet, Reuven Agami, Sarah-Maria Fendt, Diether Lambrechts, Daniela Annibali, Frederic Amant. Serine auxotrophy: A novel metabolic vulnerability of platinum-resistant ovarian cancer? [abstract]. In: Proceedings of the AACR Special Conference on Advances in Ovarian Cancer Research; 2019 Sep 13-16, 2019; Atlanta, GA. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(13_Suppl):Abstract nr A75.
Collapse
Affiliation(s)
- Tom Van Nyen
- 1Gynecological Oncology, Department of Oncology, KU Leuven, Belgium,
| | - Joao A.G. Duarte
- 2Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB; Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Matteo Rossi
- 2Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB; Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Mélanie Planque
- 2Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB; Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Esther Zaal
- 3Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands,
| | - Ali Talebi
- 4Laboratory of Lipid Metabolism and Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Stijn Moens
- 1Gynecological Oncology, Department of Oncology, KU Leuven, Belgium,
| | - Guy Eelen
- 5Laboratory of Angiogenesis and Vascular Metabolism, VIB-KU Leuven Center for Cancer Biology, VIB; Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Hugo Horlings
- 6Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands,
| | - Johan Swinnen
- 4Laboratory of Lipid Metabolism and Cancer, Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Celia Berkers
- 3Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, The Netherlands,
| | - Peter Carmeliet
- 5Laboratory of Angiogenesis and Vascular Metabolism, VIB-KU Leuven Center for Cancer Biology, VIB; Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Reuven Agami
- 7Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands,
| | - Sarah-Maria Fendt
- 2Laboratory of Cellular Metabolism and Metabolic Regulation, VIB-KU Leuven Center for Cancer Biology, VIB; Department of Oncology, KU Leuven and Leuven Cancer Institute (LKI), Belgium,
| | - Diether Lambrechts
- 8Laboratory for Translational Genetics, VIB-KU Leuven Center for Cancer Biology, VIB; Department of Human Genetics, KU Leuven, Belgium
| | - Daniela Annibali
- 1Gynecological Oncology, Department of Oncology, KU Leuven, Belgium,
| | - Frederic Amant
- 1Gynecological Oncology, Department of Oncology, KU Leuven, Belgium,
| |
Collapse
|
4
|
Van Mulder TJS, Van Nuffel D, Demolder M, De Meyer G, Moens S, Beyers KCL, Vankerckhoven VVJ, Van Damme P, Theeten H. Skin thickness measurements for optimal intradermal injections in children. Vaccine 2019; 38:763-768. [PMID: 31767463 DOI: 10.1016/j.vaccine.2019.11.002] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Revised: 10/31/2019] [Accepted: 11/01/2019] [Indexed: 01/02/2023]
Abstract
BACKGROUND In the context of precision medicine and in response to the highly needed capacity of rapid interventions towards new infectious diseases and pandemic outbreaks, intradermal immunization is gaining increased attention. However, the currently used Mantoux technique for ID injection is difficult to standardize and requires training, especially when used in children. To allow determining the maximum penetration depth and needle characteristics for the development of a platform of medical devices suited for intradermal injection, VAX-ID® and to ensure an accurate ID injection in children, the epidermal and dermal thickness at the proximal ventral and dorsal forearm (PVF & PDF) and at the deltoid region in children aged 8 weeks to 18 years were assessed. The lateral part of the upper leg was assessed as well in children aged 8 weeks to 2 years since it is a commonly used injection site in this population. MATERIALS & METHODS Mean thickness of the PVF, PDF, lateral part of the upper leg and deltoid were measured using high-frequency ultrasound. Association with gender, age and BMI was assessed using Mann-Whitney U Test, Spearman correlation and Wilcoxon Signed Ranks Test, respectively. RESULTS Results showed an overall mean skin thickness of 0.99 mm (SD: 0.14 mm) at the PVF, 1.20 mm (SD: 0.17) at the PDF, 1.28 mm (SD: 0.16) at the lateral part of the upper leg and increasing to 1.32 mm (0.25) at the deltoid region. Age and BMI correlated significantly (p < 0.001) with skin thickness at all investigated body sites. Gender did not affect skin thickness in the investigated population. CONCLUSION Significant differences in skin thickness at the PVF, PDF and deltoid region were seen according to age and BMI. An optimal needle length of 0.7 mm is advised to guarantee intradermal injection in children at all investigated injection sites. (NCT02727114).
Collapse
Affiliation(s)
- T J S Van Mulder
- Novosanis, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium; Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, BE-2610 Wilrijk, Belgium.
| | - D Van Nuffel
- Department of Biomedical Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, BE-2610 Wilrijk, Belgium
| | - M Demolder
- Department of Pharmaceutical Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, BE-2610 Wilrijk, Belgium
| | - G De Meyer
- Department of Pharmaceutical Sciences, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, BE-2610 Wilrijk, Belgium
| | - S Moens
- Voxdale, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium
| | - K C L Beyers
- Novosanis, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium; Voxdale, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium
| | - V V J Vankerckhoven
- Novosanis, Bijkhoevelaan 32c, BE-2110 Wijnegem, Belgium; Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, BE-2610 Wilrijk, Belgium
| | - P Van Damme
- Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, BE-2610 Wilrijk, Belgium
| | - H Theeten
- Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Campus Drie Eiken, Universiteitsplein 1, BE-2610 Wilrijk, Belgium
| |
Collapse
|
5
|
Debonne E, De Leyn I, Verwaeren J, Moens S, Devlieghere F, Eeckhout M, Van Bockstaele F. The influence of natural oils of blackcurrant, black cumin seed, thyme and wheat germ on dough and bread technological and microbiological quality. Lebensm Wiss Technol 2018. [DOI: 10.1016/j.lwt.2018.03.041] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
6
|
Koskas M, Depreeuw J, Moens S, Annibali D, Cuppens T, Moerman P, Lambrechts D, Amant F. Genomic Characterisation and Response to Trastuzumab and Paclitaxel in Advanced or Recurrent HER2-positive Endometrial Carcinoma. Anticancer Res 2017; 36:5381-5384. [PMID: 27798902 DOI: 10.21873/anticanres.11112] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2016] [Accepted: 09/05/2016] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM Human epidermal growth factor receptor 2 (HER2) positivity is associated with a worse prognosis in endometrial cancer (EC). Trastuzumab as a single agent did not demonstrate activity in such cases but there are no reports on its combined use with taxanes. We report the outcome in patients treated simultaneously with trastuzumab and paclitaxel for advanced or recurrent HER2-positive endometrial carcinoma and compared it to their microsatellite instability (MSI) status and PIK3CA mutational profiles. PATIENTS AND METHODS Patients with advancedor recurrent endometrial carcinoma showing HER2 overexpression (2+ or 3+ immunohistochemical staining) or HER2 amplification (fluorescence in situ hybridization (FISH) HER2/chromosome 17 centromere (CEP 17) ratio >2.0) were treated with trastuzumab (8 mg/kg) and paclitaxel (90 mg/m2) every three weeks. Evaluation of the response was assessed according to the response evaluation criteria in solid tumors (RECIST) guidelines. Endometrial tumors, sampled before the beginning of trastuzumab, were genotyped for PIK3CA hot spot mutations using Sequenom iPLEX Assay technology. RESULTS Two uterine serous adenocarcinomas and one grade 3 endometrioid adenocarcinoma showing HER2 positivity were treated with trastuzumab and paclitaxel. Between three and seven months of treatment, the three cases showed progressive disease. The genomic analysis of the three cases showed different mutational profiles. One case was found to have MSI and had one PIK3CA mutation. The two others showed no hot spot mutation for PIK3CA. CONCLUSION Even associated with paclitaxel, HER2-positive endometrial carcinomas poorly responded to trastuzumab. This report underlines the low accuracy of HER2 positivity to predict response of endometrial cancer to combined targeted therapy using trastuzumab and paclitaxel.
Collapse
Affiliation(s)
- Martin Koskas
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium .,Department of Obstetrics and Gynecology, APHP Hôpital Bichat, Diderot University Paris, Paris, France.,EA 7285, UVSQ, Montigny le Bretonneux, France
| | - Jeroen Depreeuw
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium.,Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium.,VIB, Vesalius Research Center (VRC), Leuven, Belgium
| | - Stijn Moens
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium
| | - Daniela Annibali
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium
| | - Tine Cuppens
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium
| | - Philippe Moerman
- Department of Imaging and Pathology, Division of Translational Cell and Tissue Research, KU Leuven, University of Leuven, University Hospitals Leuven, Leuven, Belgium
| | - Diether Lambrechts
- Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium.,VIB, Vesalius Research Center (VRC), Leuven, Belgium
| | - Frederic Amant
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, KU Leuven - University of Leuven, University Hospitals Leuven, Leuven, Belgium.,Center for Gynecologic Oncology Amsterdam (CGOA), Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands
| |
Collapse
|
7
|
Kuchnio A, Moens S, Bruning U, Kuchnio K, Cruys B, Thienpont B, Broux M, Ungureanu AA, Leite de Oliveira R, Bruyère F, Cuervo H, Manderveld A, Carton A, Hernandez-Fernaud JR, Zanivan S, Bartic C, Foidart JM, Noel A, Vinckier S, Lambrechts D, Dewerchin M, Mazzone M, Carmeliet P. The Cancer Cell Oxygen Sensor PHD2 Promotes Metastasis via Activation of Cancer-Associated Fibroblasts. Cell Rep 2015; 12:992-1005. [PMID: 26235614 DOI: 10.1016/j.celrep.2015.07.010] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2015] [Revised: 06/23/2015] [Accepted: 07/07/2015] [Indexed: 12/13/2022] Open
Abstract
Several questions about the role of the oxygen sensor prolyl-hydroxylase 2 (PHD2) in cancer have not been addressed. First, the role of PHD2 in metastasis has not been studied in a spontaneous tumor model. Here, we show that global PHD2 haplodeficiency reduced metastasis without affecting tumor growth. Second, it is unknown whether PHD2 regulates cancer by affecting cancer-associated fibroblasts (CAFs). We show that PHD2 haplodeficiency reduced metastasis via two mechanisms: (1) by decreasing CAF activation, matrix production, and contraction by CAFs, an effect that surprisingly relied on PHD2 deletion in cancer cells, but not in CAFs; and (2) by improving tumor vessel normalization. Third, the effect of concomitant PHD2 inhibition in malignant and stromal cells (mimicking PHD2 inhibitor treatment) is unknown. We show that global PHD2 haplodeficiency, induced not only before but also after tumor onset, impaired metastasis. These findings warrant investigation of PHD2's therapeutic potential.
Collapse
Affiliation(s)
- Anna Kuchnio
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Stijn Moens
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Ulrike Bruning
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Karol Kuchnio
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Bert Cruys
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Bernard Thienpont
- Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory for Translational Genetics, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Michaël Broux
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Andreea Alexandra Ungureanu
- Laboratory of Soft Matter and Biophysics, Department of Physics and Astronomy, KU Leuven, Celestijnenlaan 200D, 3001 Heverlee, Belgium
| | - Rodrigo Leite de Oliveira
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Molecular Oncology and Angiogenesis, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Françoise Bruyère
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Henar Cuervo
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Ann Manderveld
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - An Carton
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Juan Ramon Hernandez-Fernaud
- Laboratory of Vascular Proteomics, Cancer Research UK Beatson Institute, Switchback Road, Bearsden, Glasgow G61 1BD, UK
| | - Sara Zanivan
- Laboratory of Vascular Proteomics, Cancer Research UK Beatson Institute, Switchback Road, Bearsden, Glasgow G61 1BD, UK
| | - Carmen Bartic
- Laboratory of Soft Matter and Biophysics, Department of Physics and Astronomy, KU Leuven, Celestijnenlaan 200D, 3001 Heverlee, Belgium; IMEC, Kapeldreef 75, 3001 Heverlee, Belgium
| | - Jean-Michel Foidart
- Laboratory of Tumor and Developmental Biology, GIGA-Cancer, University of Liège, Avenue de l'Hôpital 3, 4000 Liège, Belgium
| | - Agnes Noel
- Laboratory of Tumor and Developmental Biology, GIGA-Cancer, University of Liège, Avenue de l'Hôpital 3, 4000 Liège, Belgium
| | - Stefan Vinckier
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Diether Lambrechts
- Laboratory for Translational Genetics, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory for Translational Genetics, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Mieke Dewerchin
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Massimiliano Mazzone
- Laboratory of Molecular Oncology and Angiogenesis, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Molecular Oncology and Angiogenesis, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium; Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Herestraat 49, 3000 Leuven, Belgium.
| |
Collapse
|
8
|
Verdegem D, Moens S, Stapor P, Carmeliet P. Endothelial cell metabolism: parallels and divergences with cancer cell metabolism. Cancer Metab 2014; 2:19. [PMID: 25250177 PMCID: PMC4171726 DOI: 10.1186/2049-3002-2-19] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2014] [Accepted: 08/14/2014] [Indexed: 02/08/2023] Open
Abstract
The stromal vasculature in tumors is a vital conduit of nutrients and oxygen for cancer cells. To date, the vast majority of studies have focused on unraveling the genetic basis of vessel sprouting (also termed angiogenesis). In contrast to the widely studied changes in cancer cell metabolism, insight in the metabolic regulation of angiogenesis is only just emerging. These studies show that metabolic pathways in endothelial cells (ECs) importantly regulate angiogenesis in conjunction with genetic signals. In this review, we will highlight these emerging insights in EC metabolism and discuss them in perspective of cancer cell metabolism. While it is generally assumed that cancer cells have unique metabolic adaptations, not shared by healthy non-transformed cells, we will discuss parallels and highlight differences between endothelial and cancer cell metabolism and consider possible novel therapeutic opportunities arising from targeting both cancer and endothelial cells.
Collapse
Affiliation(s)
- Dries Verdegem
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven 3000, Belgium ; Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, K.U.Leuven, Campus Gasthuisberg, Herestraat 49, box 912, Leuven 3000, Belgium
| | - Stijn Moens
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven 3000, Belgium ; Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, K.U.Leuven, Campus Gasthuisberg, Herestraat 49, box 912, Leuven 3000, Belgium
| | - Peter Stapor
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven 3000, Belgium ; Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, K.U.Leuven, Campus Gasthuisberg, Herestraat 49, box 912, Leuven 3000, Belgium
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, Department of Oncology, University of Leuven, Leuven 3000, Belgium ; Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, K.U.Leuven, Campus Gasthuisberg, Herestraat 49, box 912, Leuven 3000, Belgium
| |
Collapse
|
9
|
Stapor P, Wang X, Goveia J, Moens S, Carmeliet P. Angiogenesis revisited - role and therapeutic potential of targeting endothelial metabolism. J Cell Sci 2014; 127:4331-41. [PMID: 25179598 DOI: 10.1242/jcs.153908] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Clinically approved therapies that target angiogenesis in tumors and ocular diseases focus on controlling pro-angiogenic growth factors in order to reduce aberrant microvascular growth. Although research on angiogenesis has revealed key mechanisms that regulate tissue vascularization, therapeutic success has been limited owing to insufficient efficacy, refractoriness and tumor resistance. Emerging concepts suggest that, in addition to growth factors, vascular metabolism also regulates angiogenesis and is a viable target for manipulating the microvasculature. Recent studies show that endothelial cells rely on glycolysis for ATP production, and that the key glycolytic regulator 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) regulates angiogenesis by controlling the balance of tip versus stalk cells. As endothelial cells acquire a tip cell phenotype, they increase glycolytic production of ATP for sprouting. Furthermore, pharmacological blockade of PFKFB3 causes a transient, partial reduction in glycolysis, and reduces pathological angiogenesis with minimal systemic harm. Although further assessment of endothelial cell metabolism is necessary, these results represent a paradigm shift in anti-angiogenic therapy from targeting angiogenic factors to focusing on vascular metabolism, warranting research on the metabolic pathways that govern angiogenesis.
Collapse
Affiliation(s)
- Peter Stapor
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, B-3000 Leuven, Belgium Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, KU Leuven, B-3000 Leuven, Belgium
| | - Xingwu Wang
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, B-3000 Leuven, Belgium Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, KU Leuven, B-3000 Leuven, Belgium
| | - Jermaine Goveia
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, B-3000 Leuven, Belgium Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, KU Leuven, B-3000 Leuven, Belgium
| | - Stijn Moens
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, B-3000 Leuven, Belgium Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, KU Leuven, B-3000 Leuven, Belgium
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, B-3000 Leuven, Belgium Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, KU Leuven, B-3000 Leuven, Belgium
| |
Collapse
|
10
|
Goveia J, Zecchin A, Rodriguez FM, Moens S, Stapor P, Carmeliet P. Endothelial cell differentiation by SOX17: promoting the tip cell or stalking its neighbor instead? Circ Res 2014; 115:205-7. [PMID: 24989487 DOI: 10.1161/circresaha.114.304234] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Jermaine Goveia
- From the Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, University of Leuven, Leuven, Belgium (J.G., A.Z., F.M.R., S.M., P.S., P.C.); and Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, Belgium (J.G., A.Z., F.M., S.M., P.S., P.C.)
| | - Annalisa Zecchin
- From the Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, University of Leuven, Leuven, Belgium (J.G., A.Z., F.M.R., S.M., P.S., P.C.); and Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, Belgium (J.G., A.Z., F.M., S.M., P.S., P.C.)
| | - Francisco Morales Rodriguez
- From the Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, University of Leuven, Leuven, Belgium (J.G., A.Z., F.M.R., S.M., P.S., P.C.); and Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, Belgium (J.G., A.Z., F.M., S.M., P.S., P.C.)
| | - Stijn Moens
- From the Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, University of Leuven, Leuven, Belgium (J.G., A.Z., F.M.R., S.M., P.S., P.C.); and Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, Belgium (J.G., A.Z., F.M., S.M., P.S., P.C.)
| | - Peter Stapor
- From the Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, University of Leuven, Leuven, Belgium (J.G., A.Z., F.M.R., S.M., P.S., P.C.); and Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, Belgium (J.G., A.Z., F.M., S.M., P.S., P.C.)
| | - Peter Carmeliet
- From the Laboratory of Angiogenesis and Neurovascular link, Department of Oncology, University of Leuven, Leuven, Belgium (J.G., A.Z., F.M.R., S.M., P.S., P.C.); and Laboratory of Angiogenesis and Neurovascular link, Vesalius Research Center, VIB, Leuven, Belgium (J.G., A.Z., F.M., S.M., P.S., P.C.).
| |
Collapse
|
11
|
Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, Vinckier S, Vankelecom H, Garmyn M, Vion AC, Radtke F, Boulanger C, Gerhardt H, Dejana E, Dewerchin M, Ghesquière B, Annaert W, Agostinis P, Carmeliet P. Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014; 26:190-206. [PMID: 25117709 DOI: 10.1016/j.ccr.2014.06.025] [Citation(s) in RCA: 306] [Impact Index Per Article: 30.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2012] [Revised: 01/06/2014] [Accepted: 06/27/2014] [Indexed: 12/21/2022]
Abstract
Chloroquine (CQ) has been evaluated as an autophagy blocker for cancer treatment, but it is unknown if it acts solely by inhibiting cancer cell autophagy. We report that CQ reduced tumor growth but improved the tumor milieu. By normalizing tumor vessel structure and function and increasing perfusion, CQ reduced hypoxia, cancer cell invasion, and metastasis, while improving chemotherapy delivery and response. Inhibiting autophagy in cancer cells or endothelial cells (ECs) failed to induce such effects. CQ's vessel normalization activity relied mainly on alterations of endosomal Notch1 trafficking and signaling in ECs and was abrogated by Notch1 deletion in ECs in vivo. Thus, autophagy-independent vessel normalization by CQ restrains tumor invasion and metastasis while improving chemotherapy, supporting the use of CQ for anticancer treatment.
Collapse
MESH Headings
- Angiogenesis Inhibitors/pharmacology
- Angiogenesis Inhibitors/therapeutic use
- Animals
- Autophagy
- Autophagy-Related Protein 5
- Camptothecin/pharmacology
- Cell Line, Tumor
- Cell Proliferation/drug effects
- Chloroquine/pharmacology
- Chloroquine/therapeutic use
- Drug Synergism
- Endothelial Cells/drug effects
- Endothelial Cells/physiology
- Endothelium, Vascular/drug effects
- Endothelium, Vascular/pathology
- Humans
- Melanoma, Experimental/blood supply
- Melanoma, Experimental/drug therapy
- Melanoma, Experimental/pathology
- Mice
- Mice, Inbred C57BL
- Mice, Nude
- Microtubule-Associated Proteins/metabolism
- Neoplasm Invasiveness
- Neovascularization, Pathologic/metabolism
- Neovascularization, Pathologic/prevention & control
- Receptor, Notch1/metabolism
- Skin Neoplasms/blood supply
- Skin Neoplasms/drug therapy
- Skin Neoplasms/pathology
- Tumor Burden/drug effects
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Hannelore Maes
- Department Cellular and Molecular Medicine, Laboratory of Cell Death and Therapy, KU Leuven, B-3000 Leuven, Belgium
| | - Anna Kuchnio
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Aleksandar Peric
- Department of Human Genetics and VIB-Center for the Biology of Disease, Laboratory for Membrane Trafficking, B-3000 Leuven, Leuven 3000, Belgium
| | - Stijn Moens
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Kris Nys
- Department Cellular and Molecular Medicine, Laboratory of Cell Death and Therapy, KU Leuven, B-3000 Leuven, Belgium
| | - Katrien De Bock
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Annelies Quaegebeur
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Sandra Schoors
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Maria Georgiadou
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Jasper Wouters
- Department of Imaging & Pathology, Translational Cell and Tissue Research, KU Leuven, B-3000 Leuven, Belgium; Department of Development and Regeneration, Embryo and Stem Cells Unit, KU Leuven, B-3000 Leuven, Belgium
| | - Stefan Vinckier
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Hugo Vankelecom
- Department of Development and Regeneration, Embryo and Stem Cells Unit, KU Leuven, B-3000 Leuven, Belgium
| | - Marjan Garmyn
- Department of Oncology, Laboratory Dermatology, KU Leuven, B-3000 Leuven, Belgium
| | | | - Freddy Radtke
- Ecole Polytechnique Fédérale de Lausanne, School of Life Science, 1015 Lausanne, Switzerland; Swiss Institute for Experimental Cancer Research, 1015 Lausanne, Switzerland
| | - Chantal Boulanger
- Cardiovascular Research Center, INSERM UMR-970, Paris Cedex 15, France
| | - Holger Gerhardt
- Vascular Biology Laboratory, London Research Institute, Cancer Research UK, London WC2A 3LY, UK; Department of Oncology, Vascular Patterning Laboratory, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Vascular Patterning Laboratory, VIB, B-3000 Leuven, Belgium
| | - Elisabetta Dejana
- Vascular Biology Program, IFOM, FIRC Institute of Molecular Oncology Foundation, 20139 Milan, Italy
| | - Mieke Dewerchin
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Bart Ghesquière
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| | - Wim Annaert
- Department of Human Genetics and VIB-Center for the Biology of Disease, Laboratory for Membrane Trafficking, B-3000 Leuven, Leuven 3000, Belgium
| | - Patrizia Agostinis
- Department Cellular and Molecular Medicine, Laboratory of Cell Death and Therapy, KU Leuven, B-3000 Leuven, Belgium.
| | - Peter Carmeliet
- Department of Oncology, Laboratory of Angiogenesis and Neurovascular Link, KU Leuven, B-3000 Leuven, Belgium; Vesalius Research Center, Laboratory of Angiogenesis and Neurovascular Link, VIB, B-3000 Leuven, Belgium
| |
Collapse
|
12
|
Moens S, Goveia J, Stapor PC, Cantelmo AR, Carmeliet P. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses. Cytokine Growth Factor Rev 2014; 25:473-82. [PMID: 25169850 DOI: 10.1016/j.cytogfr.2014.07.009] [Citation(s) in RCA: 104] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Accepted: 07/15/2014] [Indexed: 12/15/2022]
Abstract
Vascular endothelial growth factor (VEGF) is a key growth factor driving angiogenesis (i.e. the formation of new blood vessels) in health and disease. Pharmacological blockade of VEGF signaling to inhibit tumor angiogenesis is clinically approved but the survival benefit is limited as patients invariably acquire resistance. This is partially mediated by the intrinsic flexibility of tumor cells to adapt to VEGF-blockade. However, it has become clear that tumor stromal cells also contribute to the resistance. Originally, VEGF was thought to specifically target endothelial cells (ECs) but it is now clear that many stromal cells also respond to VEGF signaling, making anti-VEGF therapy more complex than initially anticipated. A more comprehensive understanding of the complex responses of stromal cells to VEGF-blockade might inform the design of improved anti-angiogenic agents.
Collapse
Affiliation(s)
- Stijn Moens
- Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, K.U. Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, Leuven, Belgium
| | - Jermaine Goveia
- Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, K.U. Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, Leuven, Belgium
| | - Peter C Stapor
- Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, K.U. Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, Leuven, Belgium
| | - Anna Rita Cantelmo
- Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, K.U. Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, Leuven, Belgium
| | - Peter Carmeliet
- Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, K.U. Leuven, Campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; Laboratory of Angiogenesis & Neurovascular Link, Vesalius Research Center, VIB, Leuven, Belgium.
| |
Collapse
|
13
|
Abstract
Rather recently it has become clear that prokaryotes (Archaea and Bacteria) are able to glycosylate proteins. A literature survey revealed the different types of glycoproteins. They include mainly surface layer (S-layer) proteins, flagellins, and polysaccharide-degrading enzymes. Only in a few cases is structural information available. Many different structures have been observed that display much more variation than that observed in eukaryotes. A few studies have given evidence for the function of the prokaryotic glycoprotein glycans. Also from the biosynthetic point of view, information is rather scarce. Due to their different cell structure, prokaryotes have to use mechanisms different from those found in eukaryotes to glycosylate proteins. However, from the fragmented data available for the prokaryotic glycoproteins, similarities with the eukaryotic system can be noticed.
Collapse
Affiliation(s)
- S Moens
- F. A. Janssens Laboratory of Genetics, Catholic University of Leuven, Willem de Croylaan 42, B-3001 Heverlee, Belgium
| | | |
Collapse
|
14
|
Moens S, Schloter M, Vanderleyden J. Expression of the structural gene, laf1, encoding the flagellin of the lateral flagella in Azospirillum brasilense Sp7. J Bacteriol 1996; 178:5017-9. [PMID: 8759869 PMCID: PMC178288 DOI: 10.1128/jb.178.16.5017-5019.1996] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The induction of the lateral flagella of Azospirillum brasilense Sp7 was studied by using a translational fusion between the laf1 promoter and gusA. The fusion was induced when cells were grown on solid media but not when they were grown in broth. The fusion was also induced by incubation of liquid-grown cells with an anti-polar flagellum polyclonal antiserum. Hindrance of polar-flagellum rotation is suggested to be the signal for this induction.
Collapse
Affiliation(s)
- S Moens
- F.A. Janssens Laboratory of Genetics, Katholieke Universiteit Leuven, Heverlee, Belgium
| | | | | |
Collapse
|
15
|
Abstract
Many bacterial species are motile by means of flagella. The structure and implantation of flagella seems related to the specific environments the cells live in. In some cases, the bacteria even adapt their flagellation pattern in response to the environmental conditions they encounter. Swarming cell differentiation is a remarkable example of this phenomenon. Flagella seem to have more functions than providing motility alone. For many pathogenic species, studies have been performed on the contribution of flagella to the virulence, but the result is not clear in all cases. Flagella are generally accepted as being important virulence factors, and expression and repression of flagellation and virulence have in several cases been shown to be linked. Providing motility is always an important feature of flagella of pathogenic bacteria, but adhesive and other properties also have been attributed to these flagella. In nonpathogenic bacterial colonization, flagella are important locomotive and adhesive organelles as well. In several cases where competition between several bacterial species exists, motility by means of flagella is shown to provide a specific advantage for a bacterium. This review gives an overview of studies that have been performed on the significance of flagellation in a wide variety of processes where flagellated bacteria are involved.
Collapse
Affiliation(s)
- S Moens
- F. A. Janssens Laboratory of Genetics, Katholieke Universiteit Leuven, Heverlee, Belgium
| | | |
Collapse
|
16
|
Moens S, Michiels K, Vanderleyden J. Glycosylation of the flagellin of the polar flagellum of Azospirillum brasilense, a Gram-negative nitrogen-fixing bacterium. Microbiology (Reading) 1995. [DOI: 10.1099/13500872-141-10-2651] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
17
|
Moens S, Michiels K, Keijers V, Van Leuven F, Vanderleyden J. Cloning, sequencing, and phenotypic analysis of laf1, encoding the flagellin of the lateral flagella of Azospirillum brasilense Sp7. J Bacteriol 1995; 177:5419-26. [PMID: 7559324 PMCID: PMC177346 DOI: 10.1128/jb.177.19.5419-5426.1995] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Azospirillum brasilense can display a single polar flagellum and several lateral flagella. The A. brasilense Sp7 gene laf1, encoding the flagellin of the lateral flagella, was isolated and sequenced. The derived protein sequence is extensively similar to those of the flagellins of Rhizobium meliloti, Agrobacterium tumefaciens, Bartonella bacilliformis, and Caulobacter crescentus. An amino acid alignment shows that the flagellins of these bacteria are clustered and are clearly different from other known flagellins. A laf1 mutant, FAJ0201, was constructed by replacing an internal part of the laf1 gene by a kanamycin resistance-encoding gene cassette. The mutant is devoid of lateral flagella but still forms the polar flagellum. This phenotype is further characterized by the abolishment of the capacities to swarm on a semisolid surface and to spread from a stab inoculation in a semisolid medium. FAJ0201 shows a normal wheat root colonization pattern in the initial stage of plant root interaction.
Collapse
Affiliation(s)
- S Moens
- F. A. Janssens Laboratory of Genetics, Katholieke Universiteit Leuven, Heverlee, Belgium
| | | | | | | | | |
Collapse
|
18
|
Schloter M, Moens S, Croes C, Reidel G, Esquenet M, De Mot R, Hartmann A, Michiels K. Characterization of cell surface components of Azospirillum brasilense Sp7 as antigenic determinants for strain-specific monoclonal antibodies. Microbiology (Reading) 1994. [DOI: 10.1099/00221287-140-4-823] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
|
19
|
Croes CL, Moens S, van Bastelaere E, Vanderleyden J, Michiels KW. The polar flagellum mediates Azospirillum brasilense adsorption to wheat roots. ACTA ACUST UNITED AC 1993. [DOI: 10.1099/00221287-139-9-2261] [Citation(s) in RCA: 95] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|